Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results, Misses Expectations By $0.05 EPS

Aquestive Therapeutics (NASDAQ:AQST) issued its quarterly earnings data on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05), Zacks reports.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock traded up $0.06 during mid-day trading on Wednesday, reaching $2.79. The company’s stock had a trading volume of 1,294,031 shares, compared to its average volume of 1,762,811. Aquestive Therapeutics has a 12 month low of $2.24 and a 12 month high of $6.23. The business’s 50 day simple moving average is $3.14 and its 200 day simple moving average is $4.14. The company has a market capitalization of $254.39 million, a price-to-earnings ratio of -6.20 and a beta of 2.76.

Analyst Ratings Changes

AQST has been the subject of several research analyst reports. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $11.00.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.